A 32-year-old woman with irregular menstrual cycles and clinical features of polycystic ovary syndrome (PCOS) requests contraception. She has no contraindications to hormonal therapy. Which oral contraceptive formulation is most appropriate for managing her menstrual irregularity while providing contraception?

Explanation

## Oral Contraceptives in PCOS ### Pathophysiology of PCOS and Menstrual Irregularity **Key Point:** PCOS is characterized by hyperandrogenism, insulin resistance, and anovulation, leading to irregular or absent menstrual cycles and increased endometrial cancer risk. **High-Yield:** Combined oral contraceptive pills (COCPs) are first-line hormonal therapy in PCOS because they: 1. Suppress ovarian androgen production via LH suppression 2. Increase SHBG (sex hormone-binding globulin), reducing free androgens 3. Regulate menstrual cycles and protect the endometrium 4. Provide contraception ### Why Cyproterone Acetate-Containing Pills Are Preferred **Clinical Pearl:** Cyproterone acetate is an anti-androgen (androgen receptor antagonist) that provides additional benefit in PCOS patients with hirsutism or acne. | Feature | Cyproterone Acetate COCP | Standard COCP | Progestin-only | DMPA | |---------|--------------------------|---------------|----------------|------| | **Cycle regulation** | Excellent | Good | Poor | Variable | | **Anti-androgenic effect** | Yes (synergistic) | Modest | Minimal | None | | **Endometrial protection** | Yes | Yes | Yes | Yes | | **Hirsutism/acne improvement** | Yes | Partial | No | No | | **Menstrual predictability** | Regular | Regular | Irregular | Amenorrhea common | ### Why Each Alternative Is Suboptimal **Progestin-only pills (norethisterone):** - Do not suppress ovulation reliably in PCOS - Offer poor cycle regulation (breakthrough bleeding common) - Lack anti-androgenic effect - Less effective contraception in PCOS (higher failure rate) **Standard COCP (levonorgestrel 30 μg):** - Levonorgestrel is mildly androgenic, offsetting some benefit - Lacks dedicated anti-androgen activity - Still effective but inferior to cyproterone acetate formulations **DMPA (depot medroxyprogesterone acetate):** - Causes amenorrhea in 50% of users (undesirable in PCOS monitoring) - No anti-androgenic effect - Weight gain common (problematic in insulin-resistant PCOS) - Does not improve hirsutism or acne ### Dosing and Regimen **Mnemonic: "COCP in PCOS = Cyproterone + Estrogen + Progestin"** Cyproterone acetate formulations typically contain: - Ethinyl estradiol 35 μg (standard dose for anti-androgen effect) - Cyproterone acetate 2 mg - 21/7 regimen (21 days active, 7 days placebo) for predictable withdrawal bleeding **Tip:** Continuous or extended-cycle regimens (84/7) can be used if breakthrough bleeding occurs, but standard 21/7 is preferred initially for cycle monitoring in PCOS. [cite:ASRM Guidelines on PCOS 2013; ACOG Committee Opinion 586]